Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005059 | 0.77 | ALDH1A1 (0.39) | CYP19A1RAB9AUSP2NR1H2NR1H3 | |
| SCHEMBL27821193 | 0.73 | RAB9A (0.38) | CYP19A1RAB9AUSP2NR1H2NR1H3 | |
| SCHEMBL2794969 | 0.73 | CYP2C19 (0.39) | CYP19A1RAB9AUSP2CYP3A4CYP2C19 | |
| SCHEMBL5929626 | 0.73 | CYP2C19 (0.39) | CYP19A1RAB9AUSP2CYP3A4CYP2C19 | |
| SCHEMBL10156588 | 0.70 | CYP2C19 (0.50) | CYP3A4CYP2C19ALDH1A1KMT2A | |
| SCHEMBL27557013 | 0.68 | USP2 (0.45) | CYP19A1RAB9AUSP2NR1H2NR1H3 | |
| SCHEMBL11681348 | 0.68 | ALDH1A1 (0.42) | CYP19A1RAB9AUSP2NR1H2NR1H3 | |
| SCHEMBL5950461 | 0.67 | ESR1 (0.46) | NR1H2NR1H3CYP2C19ALDH1A1KMT2A | |
| SCHEMBL14943969 | 0.67 | CYP2C19 (0.42) | CYP2C19ALDH1A1KMT2A | |
| SCHEMBL28098161 | 0.67 | RAB9A (0.36) | CYP19A1RAB9AUSP2NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | CYP19A1 1104/4885RAB9A 3907/4885USP2 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.